Total Payments
$28,076
2024 Payments
$4,746
Companies
8
Transactions
49
Medicare Patients
982
Medicare Billing
$125,624
Payment Breakdown by Category
Research$18,484 (65.8%)
Consulting$5,700 (20.3%)
Travel$2,813 (10.0%)
Food & Beverage$1,042 (3.7%)
Education$38.00 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,484 | 19 | 65.8% |
| Consulting Fee | $5,700 | 2 | 20.3% |
| Travel and Lodging | $2,813 | 11 | 10.0% |
| Food and Beverage | $1,042 | 16 | 3.7% |
| Education | $38.00 | 1 | 0.1% |
Payments by Type
Research
$18,484
19 transactions
General
$9,593
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $18,532 | 31 | $0 (2024) |
| Eisai Inc. | $4,833 | 3 | $0 (2024) |
| Eli Lilly and Company | $2,038 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,410 | 8 | $0 (2018) |
| Genentech USA, Inc. | $1,020 | 1 | $0 (2019) |
| Medtronic USA, Inc. | $168.61 | 1 | $0 (2019) |
| Genentech, Inc. | $38.00 | 1 | $0 (2018) |
| Novartis Pharma AG | $37.28 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,746 | 2 | Eisai Inc. ($4,680) |
| 2023 | $1,738 | 2 | Eli Lilly and Company ($1,738) |
| 2022 | $17,319 | 15 | Biogen, Inc. ($16,916) |
| 2019 | $1,303 | 4 | Genentech USA, Inc. ($1,020) |
| 2018 | $1,873 | 21 | Biogen, Inc. ($1,427) |
| 2017 | $1,098 | 5 | Novartis Pharmaceuticals Corporation ($1,002) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $65.99 | General |
| 03/04/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $4,680.00 | General |
| Category: Neurology | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,358.04 | Research |
| Study: ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $380.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 12/02/2022 | Biogen, Inc. | — | — | Cash or cash equivalent | $15,018.50 | Research |
| Study: An Observational study using multimodal sensors to measure cognitive health in adults and distinguish mild cognitive impairment from normal aging. | ||||||
| 12/02/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $54.99 | General |
| 12/02/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $38.94 | General |
| 10/28/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $149.99 | General |
| 10/28/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 10/28/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $30.43 | General |
| 10/28/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $20.63 | General |
| 10/28/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $8.55 | General |
| 10/27/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $300.32 | General |
| 10/27/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $220.00 | General |
| 10/27/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $192.86 | General |
| 10/27/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $123.82 | General |
| 10/20/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $617.21 | General |
| 08/01/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $102.53 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 12/05/2019 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $63.47 | General |
| 12/05/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.60 | General |
| 05/23/2019 | Medtronic USA, Inc. | ACTIVA (Device) | Food and Beverage | In-kind items and services | $168.61 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 02/08/2019 | Genentech USA, Inc. | Activase (Biological), Cathflo Activase, TNKase | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: Metabolism & Primary Care | ||||||
| 12/08/2018 | Genentech, Inc. | Non-Covered Product (Drug) | Education | In-kind items and services | $38.00 | General |
| Category: None | ||||||
| 09/27/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $176.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Observational study using multimodal sensors to measure cognitive health in adults and distinguish mild cognitive impairment from normal aging. | Biogen, Inc. | $15,019 | 1 |
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $1,427 | 15 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,358 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $380.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 188 | 212 | $84,466 | $24,607 |
| 2022 | 3 | 266 | 326 | $163,310 | $37,989 |
| 2021 | 3 | 239 | 280 | $177,170 | $32,993 |
| 2020 | 5 | 289 | 321 | $181,071 | $30,035 |
Total Patients
982
Total Services
1,139
Medicare Billing
$125,624
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 154 | 178 | $69,057 | $19,868 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 34 | 34 | $15,409 | $4,739 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 178 | 235 | $110,848 | $26,200 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 77 | 77 | $48,808 | $11,435 | 23.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 11 | 14 | $3,654 | $353.90 | 9.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 171 | 205 | $133,230 | $23,902 | 17.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 55 | 55 | $38,720 | $8,491 | 21.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 13 | 20 | $5,220 | $599.48 | 11.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 161 | 192 | $113,494 | $17,993 | 15.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 54 | 54 | $31,197 | $7,130 | 22.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 26 | 27 | $26,973 | $2,635 | 9.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 17 | 17 | $2,546 | $1,250 | 49.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 20 | $6,311 | $809.56 | 12.8% |
| Q3014 | Telehealth originating site facility fee | Office | 2020 | 11 | 11 | $550.00 | $217.32 | 39.5% |
About Dr. Sharon Sha, MD
Dr. Sharon Sha, MD is a Neurology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1225299027.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sharon Sha, MD has received a total of $28,076 in payments from pharmaceutical and medical device companies, with $4,746 received in 2024. These payments were reported across 49 transactions from 8 companies. The most common payment nature is "" ($18,484).
As a Medicare-enrolled provider, Sha has provided services to 982 Medicare beneficiaries, totaling 1,139 services with total Medicare billing of $125,624. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Behavioral Neurology & Neuropsychiatry
- Location Stanford, CA
- Active Since 06/24/2008
- Last Updated 11/06/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1225299027
Products in Payments
- Leqembi (Drug) $4,680
- Activase (Biological) $1,020
- CNP520 (Drug) $347.95
- ACTIVA (Device) $168.61
- Non-Covered Product (Drug) $38.00
- Ofatumubab (Drug) $37.28
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Stanford
Gregory Albers, Md, MD
Neurology — Payments: $500,221
Neurology $500,221
John Day, Md, MD
Neurology — Payments: $367,934
Neurology $367,934
Robert Cowan, Md, MD
Neurology — Payments: $253,351
Neurology $253,351
Josef Parvizi, Md, Phd, MD, PHD
Neurology — Payments: $215,697
Neurology $215,697
Chitra Venkatasubramanian, Md, MD
Neurology — Payments: $206,735
Neurology $206,735
Babak Razavi, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $121,290
Neurology $121,290